LONDON, Oct 22 (Reuters) - GlaxoSmithKline kept its dividend unchanged for the third quarter, breaking a run of steadily rising payouts, as U.S. pricing pressure on its top-selling lung drug Advair eroded sales and profit. Britain's biggest drugmaker said on Wednesday its 2015 dividend was
Read more** GlaxoSmithKline rises 4.6 pct after reporting Q3 EPS of 27.9p, up 5 pct and above the 24p forecast by analysts. ** Biggest one-day rise for stock since April. ** Top riser on FTSE 100 at 1100 GMT. ** Q3 dividend maintained at 19p/shr FY 2014 div expected to be 80p, up 3 pct,
Read moreLONDON, Oct 22 (Reuters) - Drugmakers will work together to accelerate development of an Ebola vaccine and Johnson & Johnson and GlaxSmithKline, both of which have experimental vaccine candidates, have already discussed collaboration. J&J, which aims to have at least 1 million doses of its
Read moreAmino Technologies: N+1 Singer moves target price from 93p to 107p upgrading to buy. Anglo American: Liberum Capital reduces target price from 1300p to 1200p retaining its sell recommendation. ARM Holdings: UBS moves target price from 970p to 980p upgrading from neutral to buy. Deutsche Bank cuts t
Read more* MSF says priority will be treatments already available * Hopes trials can begin in November * MSF would not approve use of placebo in drug trials * Women and children should be included in tests By Daniel Flynn DAKAR, Oct 21 (Reuters) - The medical charity Medecine
Read more(Repeats to additional clients.) * Clinical trials now under way to yield data on dosage * Health workers should get GSK, NewLink vaccines in Jan * Johnson & Johnson, Russia also have candidate vaccines By Stephanie Nebehay GENEVA, Oct 21 (Reuters) - Tens of thousand
Read more* Clinical trials now under way to yield data on dosage * Health workers should get GSK, NewLink vaccines in Jan * Johnson & Johnson, Russia also have candidate vaccines By Stephanie Nebehay GENEVA, Oct 21 (Reuters) - Tens of thousands of people in West Africa are expected
Read moreGlaxosmithklline will be among the most high-profile companies to release results on Wendesday as the pharmaceutical giant reports its third-quarter figures. The drugmaker is expected to deliver sales of £5.74bn in the three months to 30 September, down from £6.51bn in the third quarter of 2013. Th
Read more